Ebselen: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   All outcomes  
Meta-analysis2 studies · 56 patientsc19early.org

Ebselen for COVID-19

Serious outcome risk
Ebselen
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (2)−130%
Mortality (2)−130%
Recovery (2)−17%
RCTs (2)−130%
RCT mortality (2)−130%
Late (2)−130%
00.511.5+
← Ebselen
reduces riskIncreased
risk →
c19early.org
October 2026

Ebselen COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Treggiari (DB RCT)−141%2.41 · 0.11–54.20death1/220/9 Treggiari (DB RCT)−125%2.25 · 0.29–17.19death4/161/9
Late treatment−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.34
All studies−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ebselen
reduces riskEbselen
increases risk →
c19early.org
October 2026

Ebselen COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Treggiari (DB RCT)−141%2.41 · 0.11–54.201/220/9 Treggiari (DB RCT)−125%2.25 · 0.29–17.194/161/9
Late treatment−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.34
All studies−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ebselen
reduces riskEbselen
increases risk →
c19early.org
October 2026

Ebselen COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Treggiari (DB RCT)−141%2.41 · 0.11–54.20death1/220/9 Treggiari (DB RCT)−125%2.25 · 0.29–17.19death4/161/9
Late treatment−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.34
All studies−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ebselen
reduces riskEbselen
increases risk →
c19early.org
October 2026

Ebselen COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Treggiari (DB RCT)−21%1.21 · 0.53–2.76no recov.16 (n)9 (n) Treggiari (DB RCT)−13%1.13 · 0.49–2.60no recov.11 (n)6 (n)
Late treatment−17%1.17 · 0.65–2.1027 (n)15 (n)17% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−17%1.17 · 0.65–2.1027 (n)15 (n)17% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Ebselen
reduces riskEbselen
increases risk →
c19early.org
October 2026

Ebselen COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Treggiari (DB RCT)−141%2.41 · 0.11–54.20death1/220/9 Treggiari (DB RCT)−125%2.25 · 0.29–17.19death4/161/9
Late treatment−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.34
All studies−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ebselen
reduces riskEbselen
increases risk →
c19early.org
October 2026

Ebselen COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Treggiari (DB RCT)−141%2.41 · 0.11–54.201/220/9 Treggiari (DB RCT)−125%2.25 · 0.29–17.194/161/9
Late treatment−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.34
All studies−130%2.30 · 0.42–12.605/381/18130% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+
Rotate screen for more detailsIncrease width for more details
← Ebselen
reduces riskEbselen
increases risk →